Chicago / Edinburgh
South Korea · Korea Exchange (KOSDAQ)

Adel

Adel is a biotechnology company researching and developing antibody therapeutics for neurodegenerative diseases such as Alzheimer's disease.

Adel (Ticker: 0181E0 KS) is a biotechnology company founded in 2016 that researches and develops antibody therapeutics for neurodegenerative diseases such as Alzheimer's disease. Its chief executive is Yoon Seung-yong. Its experimental antibody medicine ADEL-Y01 has completed a Phase 1a trial in the United States, an early stage of testing in people. Sanofi is to lead subsequent clinical testing.

The IPO is expected to begin trading on Korea Exchange (KOSDAQ) on December 2, 2026. The base offering comprises 2,170,000 shares at an indicative price range of KRW 18,000.00–25,000.00 per share. Based on the indicative midpoint of KRW 21,500.00, the base offering would represent approximately KRW 46.66 billion in gross proceeds, equivalent to approximately $35.08 million.

At the indicative midpoint, estimated IPO market capitalization is KRW 465.70 billion, or approximately $350.13 million. This is an estimated equity market capitalization at the indicative midpoint, not a final priced valuation.

The company plans to use the proceeds for follow-on candidate development, upgrades to its brain-delivery platform and the discovery of new candidates. Underwriters include Samsung Securities and Mirae Asset Securities as lead underwriters.

Prepared with IPOX® AI assistance. Information may contain errors.

Prepared with IPOX® AI assistance. Information may contain errors.

THE IPOX® NEWSLETTERS

Stay ahead of the next listing.

Research and insight from the global new listings market.

Explore our newsletters